don't expect good news!, page-29

re: what have they been up too??? ABN: 99 009 179 551
Level 1, 14 – 20 Delhi Road, North Ryde NSW 2113
PO Box 307, North Ryde NSW 1870
Tel: +61 2 9870 7330 Fax: +61 2 9888 9338
website: www.imugene.com
1
ASX ANNOUNCEMENT
New Appointments
Strengthen Product Commercialisation
Dr Paul MacLeman appointed to new Chief Operating Officer position
Dr Peter Claxton appointed to new position as Regulatory Affairs Consultant
8 November 2004, Sydney: Imugene (ASX: IMU) has appointed Dr Paul
MacLeman to the new senior position of Chief Operating Officer.
Most recently Dr MacLeman was head of Agenix’s global animal health business.
During his Agenix tenure Dr MacLeman re-structured and re-focused the
business by expanding the Agenix animal health team and re-structured the US
& EU product channels by sourcing and implementing new multi-national
distributor agreements. Results included significant sales increases with
improved margins.
This appointment is vital for the rollout of Imugene’s animal health products
across world markets. Imugene will sell certain products direct to users and will
use intermediary distributors for its other animal health products.
Commenting on the appointment, Imugene Executive Chairman, Graham
Dowland stated “Dr MacLeman has over 15 years commercial experience in the
animal health and biotechnology industry, having successfully taken biological
products from the laboratory, through regulatory, manufacturing, marketing and
launch. This appointment is extremely timely for Imugene and Dr MacLeman is a
very welcome addition to the Imugene team.”
Dr MacLeman is a qualified veterinarian and has completed an MBA.
Imugene has also appointed Dr Peter Claxton as Regulatory Affairs Consultant
to oversee the regulatory process for both the Adenoviral Vector based vaccines
and the Receptor Mimic Technology product range.
For the past eight years Dr Claxton has been consulting to the veterinary
biologicals and pharmaceuticals industries. His strengths include R&D programs
that comply with regulatory requirements, product development, technology
transfer, manufacture, quality assurance and product licensing, GMP and QA
auditing for companies producing veterinary vaccines (viral, bacterial, protozoal).
ABN: 99 009 179 551
Level 1, 14 – 20 Delhi Road, North Ryde NSW 2113
PO Box 307, North Ryde NSW 1870
Tel: +61 2 9870 7330 Fax: +61 2 9888 9338
website: www.imugene.com
2
For over 10 years prior to consulting, Dr Claxton was technical director of Arthur
Webster Pty Ltd and responsible for in-house R&D for vaccines for poultry,
companion animals and grazing animals. Dr Claxton is also a qualified
veterinarian, with a PhD in Veterinary Science and a Postgraduate Diploma in
Bacteriology from London University.
“Dr Claxton has over 30 years relevant experience in the animal health product
registration and regulatory environment in Australia and internationally. Dr
Claxton’s appointment together with Dr MacLeman’s provides Imugene with the
resources to implement its product development and commercialisation
strategies as planned. These two appointments will add to the impetus already
achieved with the development and commercialisation of our product range,” said
Mr Dowland.
END
More information:
Dr Warwick Lamb, Mr Graham Dowland,
Imugene’s Managing Director Imugene’s Executive Chairman
+61 2 9870 7330 +61 8 9322 9189
Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333
ABOUT IMUGENE:
Imugene specialises in commercialising animal health products for production animals
and pets.
Imugene’s products safely prevent disease and reduce or eliminate antibiotics and
harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain
have been linked to the emergence of dangerous resistant bacteria in people and food
residues.
Imugene owns the worldwide rights to two platform technologies. The Receptor Mimic
Technology for gastrointestinal diseases of pigs and potentially all other animal species.
Secondly, the Adenoviral Vector Delivery System for pigs and poultry delivers
Imugene’s highly effective poultry productivity enhancer.
Imugene's poultry and pig portfolio is targeting a worldwide US$3 billion annual market
and replace existing chemical and antibiotic products. Consumer demands for residue
free food and health regulatory pressures will bolster Imugene's prospects.
Visit the Imugene Website: www.imugene.com